Long-Term Efficacy of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: Data from a Pivotal Phase 3 Clinical Trial

  • Menter A
  • Sobell J
  • Silverberg J
  • et al.
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Abstract not available. This study was sponsored by Amgen Inc. and medical writing support was funded by Ortho Dermatologics.

Cite

CITATION STYLE

APA

Menter, A., Sobell, J., Silverberg, J. I., Lebwohl, M., Rastogi, S., Pillai, R., & Israel, R. J. (2018). Long-Term Efficacy of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: Data from a Pivotal Phase 3 Clinical Trial. SKIN The Journal of Cutaneous Medicine, 2, S9. https://doi.org/10.25251/skin.2.supp.9

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free